Cardiovascular Disease Risk in Women With Endometriosis

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 1, 2025

Study Completion Date

December 31, 2026

Conditions

Endometriosis

Interventions

DRUG

Elagolix

Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.

Trial Locations (1)

RECRUITING

Yale School of Medicine, New Haven

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Yale University

OTHER